Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
lobredimil
- Development stage
- Phase 2
- Lead developer
- Sanofi
- Modality
- Small Molecules
- Administration
- Intravenous
01
Overview
Lobredimil is a synthetic small molecule drug that acts as a bradykinin B2 receptor antagonist. It was developed primarily for its potential to reduce cerebral edema and improve outcomes in patients with brain tumors or traumatic brain injury by inhibiting the effects of bradykinin, a peptide involved in increasing vascular permeability and promoting inflammation. Lobredimil blocks the bradykinin B2 receptor, thereby reducing blood-brain barrier permeability and limiting fluid accumulation in the brain. The drug was investigated in clinical trials but development appears to have been discontinued.
- Other names
- RPR-100893RPR100893RPR 100893lobredimil
02
Targets
Bradykinin B2 receptor
Beyond the preview
Go deeper on lobredimil.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on lobredimil.